Tech expert and USA Today nationally-syndicated tech-life columnist Jennifer Jolly joins TODAY to share a roundup of gadgets that will make life around the house simpler, safer and smarter. Items ...

Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. Gilead Sciences beat analysts’ revenue ...

Gilead's HIV franchise remains dominant, generating $19.612 billion in 2024, but faces potential funding challenges impacting future growth. Efforts to build a cancer franchise have been mixed ...

Federal funding for HIV prevention could be slashed, according to The Wall Street Journal. Gilead Sciences fell 2.52% in premarket trading on the news. The company makes medication for treating ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and Development Expertise ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s Yuhan to help produce its HIV meds in a deal worth $80.9 million.

Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June to settle a case in federal court for $40 million that had been brought by 2,625 people living with HIV.

Cognizant has expanded its agreement with biopharmaceutical company Gilead Sciences to manage its global IT infrastructure, platforms and applications, and lead initiatives to accelerate its ...

Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show. By Rebecca Robbins and Sheryl Gay Stolberg In 2004 ...